Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2003

View Archived Issues

Spotlight on S-adenosyl-L-methionine (SAMe)

Kyoto Pharmaceutical presents novel glucose- and lipid-lowering agents

Elan and Pharmacia jointly report new series of beta-secretase inhibitors

Novel SGLT-1 inhibitors prepared and tested at Kissei

Mochida researchers identify analgesic agents resistant to metabolic degradation

Permeation enhancers discovered by Allergan scientists

New atrial-selective antiarrhythmic agents covered by Nissan Chemical patent

Yamanouchi reports novel VEGF inhibitors

Mitsubishi Pharma reports novel PARP inhibitors with utility in cerebral infarction

QRX-101 phase II trial in psoriasis cleared to begin

First clinical trial of ACP-103, targeted for treatment-induced dysfunction in Parkinson's disease

G17DT recommended for orphan drug status in E.U.

Velcade NDA submitted for multiple myeloma

Positive findings for Nastech's intranasal sumatriptan

Theratechnologies acquires new peptide with potential application in diabetes

European launch of Cialis under way

PT-141 effective in ED patients who fail to respond to Viagra

Arestin approved in Sweden

Amgen submits sBLA for Enbrel in ankylosing spondylitis

Geron reports new data on hematopoietic cell production from hESCs

Geron refocuses resources

New treatment option for COPD nearing approval in Europe

Divalproex sodium reported safer than olanzapine in bipolar disorder

Two courses of alefacept evaluated in patients with chronic plaque psoriasis

Antiinflammatory effects of omega-3 fatty acids

Teijin and Kyorin to form new company

Reduced parenteral nutrition requirement with rhGH and glutamine in short bowel syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...